Loneliness has been defined as a negative emotional state of unfulfilled intimate and social needs ([@R1]). It can also be considered as a behavioral trait, because it is stable over time ([@R2], [@R3]), difficult to alter with interventions ([@R4]), and heritable ([@R5]). Loneliness is a subjective perception of social isolation and therefore independent of objective measures such as social network size ([@R1]), making it a challenge to study in non-human animals.

Loneliness has a profoundly negative impact on psychological/behavioral processes including mental health, particularly in aging populations. For example, loneliness is associated with depression and anxiety ([@R6]--[@R8]). Longitudinal studies of cognition reported that loneliness at baseline predicted cognitive decline in recall memory over a 4-year period ([@R9]), was associated with lower levels of perceptual processing and memory at baseline ([@R10]), overall cognitive decline ([@R11]) and incident dementia ([@R12]), as well as a decline in motor function ([@R13]). The underlying molecular-genetic mechanisms of these associations are currently unknown, in part because gene expression as a function of loneliness has not yet been examined in the human brain.

Loneliness is also associated with increased risk for neurological and neurodegenerative diseases such as Alzheimer's disease (AD) ([@R10]), as well as cancer ([@R17], [@R18]), and organismal and muscular diseases and disorders that include cardiovascular disease ([@R14]--[@R16]), and dysfunction of the immune system and inflammatory disease ([@R19]--[@R21]). The molecular-genetic mechanisms underlying some of these associations have begun to be examined at the level of the transcriptome ([@R22]), in which genes responsive to glucocorticoids and genes within pro-inflammatory pathways were differentially expressed. Whether similar expression patterns are manifested in the human brain is currently unknown.

Here, we set out to examine the expression profile of mRNAs in the human brain as a function of loneliness. We took advantage of data and tissue from the Rush Memory and Aging Project (MAP), a longitudinal prospective cohort study of common chronic conditions of aging ([@R35]). We selected the nucleus accumbens as our *a priori* region of interest, based on work that had shown the nucleus accumbens to be involved in (social) reward processing ([@R36]--[@R38]), and a functional magnetic resonance imaging (fMRI) study that reported reduced activation in the nucleus accumbens of lonely individuals ([@R39]).

We used a microarray approach to measure genome-wide mRNA expression in nucleus accumbens tissue from 26 donors (see [Table 1](#T1){ref-type="table"} for demographic and related sample information) with known loneliness phenotypes, based on self-report at baseline (representing the trait-like aspects of loneliness when participants were relatively healthy, e.g., without known dementia, rather than the state-like aspects of loneliness proximate to death).

Materials/Subjects and Methods {#S1}
==============================

Subjects {#S2}
--------

All brain donors were participants in the ongoing Rush Memory and Aging Project (MAP), a cohort study of common chronic conditions of aging ([@R35]). MAP participants are older persons without known dementia at enrollment ("baseline") who agree to annual detailed evaluation and organ donation at the time of death. The evaluation includes 21 cognitive performance tests and clinical evaluation from which dementia status and the presence of mild cognitive impairment (MCI) is determined annually as described ([@R43], [@R44]). The remaining subjects had no obvious cognitive impairment (NCI). The follow-up rate exceeds 95% and the autopsy rate exceeds 80%. The study was approved by the Institutional Review Board of Rush University Medical Center and all subjects signed an informed consent and Anatomical Gift Act.

Twenty-six White, non-Hispanic individuals without a clinical diagnosis of depression (i.e., excluding individuals who were rated "probable" or "highly probable" to be depressed by a clinician) at baseline were selected out of a pool of 247 MAP participants with reported loneliness data (see next section) by stratified random sub-sampling from a convenience sample from the top and bottom quartiles of loneliness scores (N=13 each), and matched for the number of females (N=6) in these quartiles. From these donors, nucleus accumbens tissue was collected for RNA expression analysis (see below). There was no significant difference between lonely and non-lonely individuals in education, age at death, last MMSE prior to death, agonic state prior to death, or a host of other potential confounds (see [Table 1](#T1){ref-type="table"} for details, and [Supplementary Table 1](#SD2){ref-type="supplementary-material"} for individual medication history). However, consistent with its known association with dementia ([@R10]), lonely individuals exhibited significantly poorer cognitive function and were more likely to have dementia and to meet pathologic criteria for AD. There was no significant difference between the two groups with respect to RNA quality control measures.

Self-Report Measures {#S3}
--------------------

Self-reported loneliness scores were collected annually. In a previous study of the MAP cohort there was no evidence of a linear or non-liner change in loneliness over up to five annual evaluations ([@R10]), consistent with earlier work that conceptualizes loneliness as trait-like ([@R2]). Self-reported loneliness scores were based on the average score from five response items scored on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree): 1. "I experience a general sense of emptiness"; 2. "I miss having people around"; 3. "I feel like I don't have enough friends"; 4. "I often feel abandoned"; 5. "I miss having a really close friend" as previously described ([@R10]).

Brain tissue {#S4}
------------

At autopsy, the brainstem was removed and the brain hemisected. One hemisphere was cut into 1cm slabs in a plexiglass jig, put into individual freezer bags, placed on a metal plate, and put into a −80° freezer. This tissue was the source of the gene-expression studies. A complete neuropathologic evaluation was performed that included the determination of pathologic AD by NIA-Reagan criteria as described ([@R45]).

RNA extraction, Array Platform, and Analysis {#S5}
--------------------------------------------

Total RNA was isolated from frozen nucleus accumbens tissue using TRI Reagent (Sigma-Aldrich) followed by clean-up using the RNeasy kit (Qiagen). RNA quantity and quality were measured by NanoDrop ND-1000 and RNA integrity was assessed by standard denaturing agarose gel electrophoresis. Each individual's sample was then prepared for the Arraystar Human LncRNA Array v2.0, which was designed for the global profiling of 30,215 human mRNA and 33,045 lncRNAs transcripts. On this array, each transcript is represented by a specific exon or splice junction probe to identify individual transcript accurately. The Arraystar Human LncRNA Array v2.0 contains positive probes for housekeeping genes and negative probes for hybridization quality control.

Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology). Hybridized arrays were washed, fixed and scanned using the Agilent DNA Microarray Scanner (part number G2505C). Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images. Quantile normalization and subsequent data processing were performed using the GeneSpring GX v11.5.1 software package (Agilent Technologies). After quantile normalization of the raw data, mRNAs for which at least 20 out of 26 samples had flags in Present or Marginal ("All Targets Value") were chosen for further data analysis. Raw, normalized, and meta-data were deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database under accession number GSE80696.

### Data analysis of mRNAs {#S6}

To analyze the association of loneliness with mRNA expression in nucleus accumbens, we used a multiple regression model, in which loneliness at baseline was entered as a continuous variable of interest and that included the following additional potential confounds: age at baseline, global cognition proximate to death, and Reagan AD score (a similar analysis, based on a logistic regression analysis in which loneliness was entered as a binary categorical variable -- high versus low -- produced very similar results; data not shown). The global cognition measure was based on 19 cognitive function tests converted to z-scores and averaged as previously reported ([@R10]). Overall diagnostic category was Alzheimer's disease and mild cognitive impairment (MCI) as previously described ([@R10], [@R43], [@R46]). Persons without dementia or MCI were classified as no cognitive impairment. To identify differentially expressed transcripts and genes (DEGs), we screened for mRNAs with FDR-corrected p-values of \< .05 and Fold-Change of ≥ \|2.0\|. These transcripts were then analyzed using QIAGEN's Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, [www.qiagen.com/ingenuity](www.qiagen.com/ingenuity); Content version: 26127183; Release Date: 2015-11-30). Additional analyses were conducted using Gene Set Enrichment Analysis ([@R47]) v2.2.2, based on differentially expressed transcripts on a pre-ranked (by fold-change) list, compared against two curated Alzheimer's Disease gene sets (MSigDB files: Blalock_Alzheimers_disease_up, Blalock Alzheimers_disease_down, ([@R48])).

Real-time PCR Validation {#S7}
------------------------

Twelve DEGs (ACAT2, AIG1, CART, GARS, GLRB, HAMP, LILRA2, MAPK8, OXTR, SNX7, TAC1, TSPAN7; [Supplementary Table 2](#SD3){ref-type="supplementary-material"}) were selected for validation using RT-qPCR. Relative expression values of transcripts were determined in accordance with the standard curve and then normalized to GAPDH by calculating the ratio between the concentration of the target gene and that of the housekeeping gene. Normalized intensities of GAPDH expression were constant across all 26 samples ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}), suggesting stable expression of GAPDH as an endogenous control. Data analysis was performed using ABI7900 Analysis Software SDS2.3.

Results {#S8}
=======

Stability of Loneliness {#S9}
-----------------------

Loneliness can be viewed as both a state and a trait, and it is plausible that the level of loneliness changes near the end of life. Self-reported loneliness measures were available at baseline (2.3 years prior to death), when participants were relatively healthy (e.g., without known dementia) and at last visit proximate (0.9 years) to death. Levels of loneliness were stable within-subjects across these two visits (test-retest correlation r = 0.62, p = 0.0007; [Supplementary Figure 2](#SD10){ref-type="supplementary-material"}).

Analysis of differentially expressed genes (DEGs) as a function of loneliness {#S10}
-----------------------------------------------------------------------------

We identified 1 710 transcripts from 1 599 unique DEGs as a function of loneliness reported at baseline, based on a screen of FDR-corrected significance level of p \< 0.05 and a minimum fold-change of \|2\|.

The complete list of transcripts, along with fold-change and significance levels, is presented in [Supplementary Table 3](#SD4){ref-type="supplementary-material"}. The ten most over- and under-expressed mRNAs in lonely individuals, their GO and fold-change information are listed in [Table 2](#T2){ref-type="table"}. [Figure 1](#F1){ref-type="fig"} shows individual (normalized) expression values for the five most over- and under-expressed mRNAs, respectively.

### DEGs associated with behavior {#S11}

In the category of "Top Diseases and Bio Functions: Physiological System Development and Function", IPA identified "Behavior" as the top-scoring gene set, which is presented in [Supplementary Table 4](#SD5){ref-type="supplementary-material"}.

### DEG sets associated with diseases and disorders {#S12}

In the category of "Top Diseases and Bio Functions: Diseases and Disorders", IPA identified these sets: (1) "neurological disease", (2) "psychological disorders", (3) "cancer", (4) "organismal injury and abnormalities" and (5) "skeletal and muscular disorders", which are presented in [Supplementary Tables 5](#SD6){ref-type="supplementary-material"} to [9](#SD12){ref-type="supplementary-material"}.

### Pleiotropic genes {#S13}

We next identified pleiotropic genes by cross-referencing across these sets by Venn diagram ([@R49]) (for ease of presentation, sets for "behavior" and "psychological disorders" were combined into one category, as were sets for "organismal injury and abnormalities" and "skeletal and muscular disorders"), as shown in [Figure 2](#F2){ref-type="fig"}, and listed in [Supplementary Table 10](#SD13){ref-type="supplementary-material"}. One-hundred-seventy-seven genes were most pleiotropic, participating in all four gene sets ([Supplementary Table 10, column J](#SD13){ref-type="supplementary-material"}). To determine their common molecular and cellular functions, these 177 genes were subjected to a secondary IPA analysis, which attributed these functions: cell death and survival, cell-to-cell signaling and interaction, molecular transport, lipid metabolism, and small molecule biochemistry. The complete set of genes is provided in [Supplementary Table 11](#SD14){ref-type="supplementary-material"}.

### Canonical Pathways of DEGs {#S14}

IPA identified as the top-5 canonical pathways: mitochondrial dysfunction, oxidative phosphorylation, TCA Cycle II, protein ubiquitination, and assembly of RNA polymerase II complex. The complete list of significant canonical pathways is given in [Supplementary Table 12](#SD15){ref-type="supplementary-material"}.

### Upstream regulators and regulator effect networks {#S15}

We next conducted an upstream regulator analysis in IPA to evaluate whether apparently disparate gene sets (e.g., gene sets associated with psychological/behavioral processes versus cancer) are regulated by common upstream molecules. Molecules were screened to include genes, RNAs, and proteins, and satisfied a statistical screen of IPA activation z-scores of \|2\| or greater, and overlap p-values of p\<0.05. We identified 23 upstream regulators (listed in [Supplementary Table 13](#SD16){ref-type="supplementary-material"}) that included ligand-dependent nuclear receptors, kinases, transcription regulators, phosphatases, enzymes, microRNAs, and other molecules. Ten of these upstream regulators also participate in mechanistic networks with other regulators, with whom they share a significant overlap in the regulation of downstream genes; these mechanistic networks are shown in [Figure 3](#F3){ref-type="fig"}. In order to understand how these upstream regulators might have functional downstream effects, we used IPA's Regulator Effect Networks analysis, which identified four sets of networks, shown in [Supplementary Figure 3](#SD11){ref-type="supplementary-material"}, that play a role in (1) synthesis of purine nucleotides, purine ribonucleotides, metabolism of nucleoside triphosphate; (2) inflammation of the heart; (3) movement disorders; and (4) infection by RNA virus.

Gene Set Enrichment Analysis (GSEA) {#S16}
-----------------------------------

To examine potential links between DEGs and previously reported AD genes, we selected two curated AD gene sets (MSigDB files: Blalock_Alzheimers_disease_up, Blalock Alzheimers_disease_down, ([@R48])). Using a screening threshold of FDR-corrected p-values of \< 0.05, both sets were significantly enriched ([Supplementary Table 14](#SD17){ref-type="supplementary-material"}; Blalock_Alzheimers_disease_up: Enrichment score (ES) = -0.16, normalized ES = −1.95, FDR q-val \< 0.001; Blalock\_ Alzheimers_disease down: Enrichment score (ES) = 0.33, normalized ES = 2.65, FDR q-val \< 0.001).

Discussion {#S17}
==========

Loneliness is associated with impaired psychological/behavioral processes including mental health ([@R8]--[@R11], [@R13]), as well as neurodegenerative and other physical diseases ([@R10], [@R14]--[@R21]). Prior work focused on differential gene expression in peripheral tissue ([@R22], [@R50]) and differential neural activation ([@R39]), but has not yet examined differential gene expression in the brain. Here, we investigated genome-wide RNA expression profiles as a function of loneliness in the postmortem brain. We correlated gene expression with loneliness at baseline to capture its trait-related aspects, when participants were relatively healthy; loneliness proximate to death would more likely capture state-related aspects, when participants may have been subject to mental and physical decline. We focused on differentially expressed genes (DEGs) in the nucleus accumbens, based on prior work that associated this region with loneliness, and with the processing of social rewards and stimuli ([@R36]--[@R39]).

Consistent with the view that loneliness is a trait-like phenotype, we observed that within-subject repeated measures of loneliness at baseline (2.3 years prior to death) and at last visit (0.9 years prior to death) were stable.

Loneliness at baseline was associated with differential expression of large numbers of genes in the nucleus accumbens. It was striking that IPA identified "Behavior" as the top-scoring biological function in the "Physiological Systems Development and Function" category, containing gene sets that fell into three distinct behavioral sub-categories: affective/social, cognitive, and motor, corresponding to deficits observed in lonely individuals. For example, in the affective/social sub-category, the largest group of genes was related to emotional behavior and anxiety. Indeed, loneliness is associated with social anxiety, even after controlling for level of depression ([@R51]). One of the genes in this set was *Cocaine and Amphetamine regulated Transcript Protein (CARTPT,* or *CART*). Indeed, *CART* was the highest up-regulated gene overall.

CART is abundantly expressed in the brain, including nucleus accumbens ([@R52]). In rodents, it is associated with reduced social interactions ([@R53]). In humans, loneliness is associated with high levels of stress hormones ([@R2]), and CART is expressed abundantly across all three levels of the hypothalamic--pituitary--adrenal (HPA) stress axis ([@R54]). Finally, CART interacts with dopamine (DA) ([@R55]) and, when infused into the nucleus accumbens, counters the behavioral effects of DA ([@R56]). It is therefore plausible, albeit speculative, that the DA-countering actions of high levels of CART may contribute to reduced nucleus accumbens activation in lonely individuals ([@R39]), which may make social interactions feel less rewarding ([@R40]) and diminish the experience of social uplifts ([@R2]). It is unknown whether these elevated levels of CART reflect a cause (if any) or consequence of subjective social isolation.

IPA identified (1) "neurological disease", (2) "psychological disorders", (3) "cancer", (4) "organismal injury and abnormalities", and (5) "skeletal and muscular disorders" as the top-scoring biological functions in the "Diseases and Disorders" category. Furthermore, GSE analysis identified links with 169 AD-related genes. This suggests that at least some genes involved in AD may also be involved in loneliness, based on unknown mechanisms. The causal relationship, if any, between loneliness at baseline and expression of these disease-related gene sets in postmortem tissue remains uncertain in the absence of baseline gene expression data. On the one hand, loneliness at baseline may indeed predict expression of disease-related genes in the nucleus accumbens by an average of 2.3 years at the time of death. On the other hand, the observed expression pattern could be causal in the opposite direction, such that the observed level of loneliness at baseline may have resulted from as-yet-undiagnosed, subclinical brain disease.

We identified a number of differentially expressed canonical pathways, which can be interpreted in light of patient history. For example, among the most significant differentially expressed canonical pathways were mitochondrial dysfunction, oxidative phosphorylation, and protein ubiquitination. In this study cohort, a larger proportion of lonely than non-lonely individuals met pathologic criteria for AD at the time of death (our analyses controlled for AD status), and mitochondrial dysfunction may be the primary driver of AD pathology ([@R57]--[@R59]). Oxidative phosphorylation within neuronal mitochondria may reflect reduced neuronal energy demands in the early stages of AD ([@R61], [@R62]). Protein ubiquitination is a mechanism by which misfolded proteins may be tagged for removal by the ubiquitin-proteasome (UPS) and the autophagy-lysomal pathways (ALP), and this process may be impaired in AD ([@R60]).

Our analyses allow us to begin examining the underlying molecular and regulatory architecture of the many disparate loneliness-associated behavioral and disease phenotypes. Given that the assignment of differentially expressed mRNAs to particular functional domains by IPA and GSEA was algorithmically based and hence bias-free, it is therefore remarkable that many of the differentially expressed genes had previously been associated with behavioral and disease-related processes associated with loneliness. Using these analytic tools, we identified many pleiotropic DEGs associated with more than one of these phenotypes. Indeed, a subset of genes was associated with all of these phenotypes, and this subset was characterized by playing a role in critical cellular and molecular functions. For example, the involvement of these most-pleiotropic DEGs in cell death could play a role in diminishing cell health in the nucleus accumbens, contributing to a behavioral phenotype that is less responsive to (social) reward, and have downstream effects on the expression of other genes.

In addition to pleiotropy, we conducted formal network analyses to identify upstream regulators of DEGs, mechanistic networks of such regulators, and regulator effect networks. For example, MYC (V-myc myelocytomatosis viral related oncogene) is an upstream regulator of 90 downstream target genes; it is also a proto-oncogene that itself was over-expressed in lonely individuals (FC 3.0). Within its mechanistic network, MYC controls such critical regulators as TP53 (Tumor Suppressor Protein 53), which has protective functions, CREB (cAMP response element-binding protein), which is a ubiquitous transcription factor with central roles in learning and memory, and NR3C1 (glucocorticoid receptor) which plays a role in the stress response. Among identified regulator effect networks are two that are involved in inflammation of the heart and in movement disorders, respectively, and loneliness is associated with cardiovascular disease ([@R14]--[@R16]), and decline in motor function ([@R13]). An intriguing speculation to emerge from these data is that apparently unrelated sequelae of loneliness, which may range from cognitive decline to a wide range of different diseases, may reflect an underlying genetic network architecture of pleiotropic genes and networks.

A limitation of the current study is the sample size, although it is comparable with other recent gene expression profiling studies ([@R64], [@R65]). Despite the relatively small sample size, results were robust, based on FDR-corrected statistical and fold-change thresholds and modeled to control for age at baseline, global cognition at last visit, and AD status. Statistical controls notwithstanding, the correlation of AD with loneliness in this sample makes it difficult to dissociate differential gene expression as a function of loneliness per se from gene expression as a function of AD, and future studies of the neuro-genomics of loneliness would benefit from samples that are not affected by dementia.

Another limitation of the study is that extraction of the tissue was conducted without the removal of blood cells and vessels. This represents a potential confound, since the source of (some) DEGs could have been blood leukocytes rather than neuronal tissue per se. Future studies will need to address this possibility by removing blood and blood vessels prior to assaying the tissue.

In the absence of longitudinal, repeated measures of both loneliness and gene expression, we cannot determine the direction of causality, if any. On the one hand, the experience of social isolation could be the result of brain structural and functional features that could be shaped, in part, by inherited gene variation, consistent with heritability studies of loneliness ([@R5]). If this is the case, then future large-scale studies of loneliness could investigate polymorphic variation in DNA sequences. Our study now provides a large number of candidate genes stratified across a number of disease categories that should be examined for such structural variants. On the other hand, the experience of social isolation could lead to large-scale dynamic changes in gene expression. Several plausible mechanisms come to mind. One mechanism could involve the activation of genes containing glucocorticoid response elements ([@R22], [@R66]) or other response elements that are sensitive to other stress-related signaling pathways, as loneliness is associated with differential activation of cortisol and the HPA axis ([@R2], [@R67], [@R68]). Another mechanism could involve activation of epigenetic processes such as CpG methylation, which has been shown to vary as a function of psychosocial stress ([@R69]--[@R72]), and which also has been shown to moderate craving-related behavior through gene methylation in the nucleus accumbens ([@R73]). Taken together, our results identify novel targets for future mechanistic studies of gene networks in nucleus accumbens and gene regulatory mechanisms across a variety of diseases, including AD, exacerbated by loneliness.
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  Nucleus Accumbens Cohort                                                                                                                                                        Low Loneliness   High Loneliness   t-test        chi-square
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ----------------- ------------- ------------
  **Sample Size**                                                                                                                                                                 13 (6 F)         13 (6 F)                        
  **Loneliness score (1--4) at initial visit (M, sd)**                                                                                                                            1.7 (0.4)        3.2 (0.3)         p \< 0.0001   
  **Interval: initial visit to death in years (M, sd)**                                                                                                                           2.6 (1.1)        2.1 (0.8)         p = 0.20      
  **Loneliness score (1--4) at last visit (M, sd)**                                                                                                                               2.0 (0.7)        3.0 (0.6)         p = 0.0003    
  **Interval: last visit to death in years (M, sd)**                                                                                                                              0.9 (0.4)        0.9 (0.7)         p = 0.85      
  ***[Demographics]{.ul}***                                                                                                                                                                                                        
  **Education in years (M, sd)**                                                                                                                                                  15.1 (3.0)       14.2 (3.6)        p = 0.52      
  **Age at initial visit (M, sd)**                                                                                                                                                81.9 (7.1)       87.0 (5.2)        p = 0.05      
  **Age at last visit (M, sd)**                                                                                                                                                   83.7 (7.4)       88.1 (5.5)        p = 0.09      
  **Age at death (M, sd)**                                                                                                                                                        84.6 (7.5)       89.1 (5.2)        p = 0.09      
  ***[Cognitive and Neurodegenerative Measures]{.ul}***                                                                                                                                                                            
  **Last MMSE prior to death (M, sd)**                                                                                                                                            24.5 (6.8)       20.6 (8.0)        p = 0.19      
  **Clinical interval, last MMSE prior to death in days (M, sd)**                                                                                                                 283.92 (173.9)   222.15 (72.6)     p = 0.25      
  **Global Cognition last visit**                                                                                                                                                 −0.2 (0.9)       −1.1 (0.8)        p\<.02        
  **Final clinical diagnosis of Parkinson's (yes/no)**                                                                                                                            3/10             0/13                            
  **ApoE genotype**                                                                                                                                                                                                                p = 0.109
   ***E2E2***                                                                                                                                                                     0                0                               
   ***E2E3***                                                                                                                                                                     3                1                               
   ***E2E4***                                                                                                                                                                     1                0                               
   ***E3E3***                                                                                                                                                                     9                8                               
   ***E3E4***                                                                                                                                                                     0                4                               
   ***E4E4***                                                                                                                                                                     0                0                               
  **Braak Stage**                                                                                                                                                                                                                  p = 0.018
   ***I***                                                                                                                                                                        5                0                               
   ***II***                                                                                                                                                                       2                0                               
   ***III***                                                                                                                                                                      5                6                               
   ***IV***                                                                                                                                                                       0                3                               
   ***V***                                                                                                                                                                        1                4                               
   ***VI***                                                                                                                                                                       0                0                               
  **Assessment of neuritic plaques**                                                                                                                                                                                               p = 0.026
   ***definite***                                                                                                                                                                 4                3                               
   ***probable***                                                                                                                                                                 2                9                               
   ***possible***                                                                                                                                                                 2                0                               
   ***no AD***                                                                                                                                                                    5                1                               
  **NIA Reagan score**                                                                                                                                                                                                             p = 0.015
   ***high likelihood***                                                                                                                                                          1                2                               
   ***intermediate likelihood***                                                                                                                                                  4                10                              
   ***low likelihood***                                                                                                                                                           8                1                               
   ***no AD***                                                                                                                                                                    0                0                               
  **Overall cognitive diagnostic category**                                                                                                                                                                                        p = 0.196
   ***no cognitive impairment***                                                                                                                                                  6                2                               
   ***mild cognitive impairment***                                                                                                                                                3                5                               
   ***Alzheimer's disease (AD)***                                                                                                                                                 4                6                               
  ***[Life Style]{.ul}***                                                                                                                                                                                                          
  **Grams of alcohol per day (M, sd)**                                                                                                                                            3.2 (10.4)       6.4 (11.5)        p = 0.46      
  **Lifetime daily alcohol intake (LDAI) at baseline**                                                                                                                            0.4 (0.9)        0.5 (0.7)         p = 0.91      
  **Smoking quantity at baseline (cigarettes/day: M, sd)**                                                                                                                        13.8 (15.1)      20.0 (11.4)       p = 0.46      
  **Smoking at baseline**                                                                                                                                                                                                          p = 0.691
   ***never***                                                                                                                                                                    8                7                               
   ***former smoker***                                                                                                                                                            5                6                               
   ***current smoker***                                                                                                                                                           0                0                               
  **Body Mass Index at baseline**                                                                                                                                                 25.0 (3.6)       24.2 (1.8)        p = 0.50      
  **Body Mass Index at last visit**                                                                                                                                               24.4 (3.7)       24.0 (2.3)        p = 0.76      
  ***[Medical Conditions]{.ul}***                                                                                                                                                                                                  
  **Clinician Rating of Depression at baseline**                                                                                                                                                                                   p = 0.141
   ***not present***                                                                                                                                                              13               11                              
   ***possible***                                                                                                                                                                 0                2                               
   ***probable***                                                                                                                                                                 0                0                               
   ***highly probable***                                                                                                                                                          0                0                               
  **Clinician Rating of Depression at last visit**                                                                                                                                                                                 p = 0.336
   ***not present***                                                                                                                                                              12               10                              
   ***possible***                                                                                                                                                                 1                2                               
   ***probable***                                                                                                                                                                 0                1                               
   ***highly probable***                                                                                                                                                          0                0                               
  **Hypertension ever (yes/no)**                                                                                                                                                  6/7              6/7                             p = 1.0
  **Cancer ever (yes/no)**                                                                                                                                                        5/8              2/11                            p = 0.185
  **History of Diabetes (yes/no)**                                                                                                                                                1/12             1/12                            p = 1.0
  **History of head injury with loss of consciousness (yes/no)**                                                                                                                  1/12             0/13                            p = 0.308
  **History of thyroid disease (yes/no)**                                                                                                                                         3/10             1/12                            p = 0.277
  **History of heart condition (yes/no)**                                                                                                                                         3/10             5/8                             p = 0.395
  **History of congestive heart failure (yes/no)**                                                                                                                                1/12             1/12                            p = 1.0
  **History of claudication (yes/no)**                                                                                                                                            1/12             2/11                            p = 0.539
  **Clinical diagnosis of stroke ever (yes/no)**                                                                                                                                  2/11             3/10                            p = 0.619
  **Prescription medication during 2 weeks prior to death**                                                                                                                                                                        p = 0.156
   ***yes***                                                                                                                                                                      9                10                              
   ***no***                                                                                                                                                                       0                0                               
   ***don't know***                                                                                                                                                               2                0                               
   ***no answer***                                                                                                                                                                2                3                               
  **Vitamins taken during 2 weeks prior to death**                                                                                                                                                                                 p = 0.012
   ***yes***                                                                                                                                                                      2                8                               
   ***no***                                                                                                                                                                       5                2                               
   ***don't know***                                                                                                                                                               4                0                               
   ***no answer***                                                                                                                                                                2                3                               
  **Other nonprescription medicines taken during 2 weeks prior to death (pain medication, laxatives or bowel medicines, cold and cough, sleep, antacids or stomach medicines)**                                                    p = 0.257
   ***yes***                                                                                                                                                                      6                8                               
   ***no***                                                                                                                                                                       2                2                               
   ***don't know***                                                                                                                                                               3                0                               
   ***no answer***                                                                                                                                                                2                3                               
  ***[Deceased - Post Mortem information]{.ul}***                                                                                                                                                                                  
  **Agonal State Information**                                                                                                                                                                                                     
   ***died in sleep (yes/no/don't know)***                                                                                                                                        2/9/0            2/7/1                           p = 0.547
   ***died unexpectedly (yes/no)***                                                                                                                                               1/10             1/9                             p = 0.943
   ***had major surgery with anaesthesia within two weeks prior to death (yes/no)***                                                                                              1/9              0/9                             p = 0.330
   ***breathing difficulty in the 3 days prior to death (yes/suspect/no)***                                                                                                       5/1/4            7/0/2                           p = 0.377
   ***fever in the 3 days prior to death (yes/suspect/no/don't know)***                                                                                                           3/1/3/3          4/0/5/0                         p = 0.203
   ***infection in the 3 days prior to death (yes/suspect/no)***                                                                                                                  4/2/4            2/0/7                           p = 0.179
   ***unconscious in the hour prior to death (yes/suspect/no)***                                                                                                                  9/0/1            5/1/3                           p = 0.212
   ***on ventilator in the hour prior to death (yes/no)***                                                                                                                        0/10             0/9                             
  **Post Mortem Interval in mins (M, sd)**                                                                                                                                        340 (109)        350 (128)         p = 0.83      
  **RNA OD 260/280 Ratio**                                                                                                                                                        2.0 (.05)        2.0 (.03)         p = 0.50      
  **RNA OD 260/230 Ration**                                                                                                                                                       2.1 (.05)        2.1 (.07)         p = 0.13      

  mRNA over-expressed in lonely Individuals                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ------------------------------------------- ------ ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------- ------------------------------------------------------------------- ----- ------
  CARTPT                                      9607   Hs.1707     GO:0003674\|GO:0007186\|GO:0000186\|GO:0008343\|GO:0007267\|GO:0001678\|GO:0009267\|GO:0032922\|GO:0032099\|GO:0032099\|GO:0045779\|GO:0070093\|GO:0045671\|GO:0007218\|GO:0045777\|GO:0032812\|GO:0051971\|GO:0046850\|GO:0050796\|GO:0007165\|GO:0070253\|GO:0007268\|GO:0005576\|GO:0005615\|GO:0005615                                                                                                                                                   NP_004282      CART prepropeptide                                                  4.1   16.8
  UCHL1                                       7345   Hs.518731   GO:0031694\|GO:0004197\|GO:0016874\|GO:0008242\|GO:0008233\|GO:0005515\|GO:0043130\|GO:0004221\|GO:0007628\|GO:0007412\|GO:0019896\|GO:0008283\|GO:0042755\|GO:0043407\|GO:0050905\|GO:0016579\|GO:0006950\|GO:0006511\|GO:0030424\|GO:0005737\|GO:0005737\|GO:0005737\|GO:0005829\|GO:0005622\|GO:0043231\|GO:0043025\|GO:0005730\|GO:0005634\|GO:0005886\|GO:0005886                                                                                       NP_004172      Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)   3.4   10.8
  ATP6V1E1                                    529    Hs.517338   GO:0008553\|GO:0016787\|GO:0005515\|GO:0046961\|GO:0015991\|GO:0006879\|GO:0008286\|GO:0006811\|GO:0015992\|GO:0033572\|GO:0055085\|GO:0016324\|GO:0005737\|GO:0005829\|GO:0005829\|GO:0005829\|GO:0005768\|GO:0005739\|GO:0016469\|GO:0033178                                                                                                                                                                                                               NP_001687      ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1             3.2   9.4
  GLRB                                        2743   Hs.32973    GO:0005230\|GO:0016934\|GO:0016934\|GO:0016933\|GO:0016594\|GO:0005216\|GO:0005515\|GO:0004872\|GO:0007340\|GO:0007628\|GO:0034220\|GO:0006811\|GO:0007399\|GO:0007218\|GO:0051291\|GO:0042391\|GO:0060013\|GO:0001964\|GO:0007268\|GO:0060012\|GO:0055085\|GO:0007601\|GO:0030054\|GO:0034707\|GO:0005887\|GO:0005624\|GO:0005886\|GO:0045211\|GO:0045202                                                                                                   NP_001159533   Glycine receptor, beta                                              3.1   8.5
  GAP43                                       2596   Hs.134974   GO:0005516\|GO:0005515\|GO:0007205\|GO:0030154\|GO:0007275\|GO:0007399\|GO:0040008\|GO:0009611\|GO:0030054\|GO:0042995\|GO:0032584\|GO:0005886\|GO:0045202                                                                                                                                                                                                                                                                                                   NP_002036      Growth associated protein 43                                        3.0   7.8
  RCN2                                        5955   Hs.79088    GO:0005509\|GO:0005783\|GO:0005788                                                                                                                                                                                                                                                                                                                                                                                                                           NP_002893      Reticulocalbin 2, EF-hand calcium binding domain                    2.9   7.6
  ASPH                                        444    Hs.332422   GO:0005488\|GO:0005509\|GO:0009055\|GO:0016491\|GO:0016702\|GO:0004597\|GO:0008307\|GO:0005198\|GO:0006936\|GO:0055114\|GO:0018193\|GO:0005783\|GO:0005789\|GO:0030176\|GO:0016021\|GO:0016020                                                                                                                                                                                                                                                               NP_115857      Aspartate beta-hydroxylase                                          2.9   7.2
  PAM                                         5066   Hs.369430   GO:0031418\|GO:0005507\|GO:0016829\|GO:0046872\|GO:0004598\|GO:0004504\|GO:0005515\|GO:0009987\|GO:0055114\|GO:0006518\|GO:0006464\|GO:0005576\|GO:0016021\|GO:0016020\|GO:0030141                                                                                                                                                                                                                                                                           NP_620177      Peptidylglycine alpha-amidating monooxygenase                       2.8   6.9
  TAC1                                        6863   Hs.2563     GO:0007267\|GO:0009582\|GO:0007204\|GO:0007320\|GO:0007218\|GO:0007268\|GO:0007217\|GO:0005576\|GO:0005576\|GO:0005615                                                                                                                                                                                                                                                                                                                                       NP_054704      Tachykinin, precursor 1                                             2.8   6.9
  SFRP5                                       6425   Hs.279565   GO:0030165\|GO:0042813\|GO:0017147\|GO:0061133\|GO:0016055\|GO:0009653\|GO:0006915\|GO:0060028\|GO:0048546\|GO:0009790\|GO:0001736\|GO:0007163\|GO:0001654\|GO:0030900\|GO:0008406\|GO:0030514\|GO:0043508\|GO:0090090\|GO:0035414\|GO:0008285\|GO:2000041\|GO:0051898\|GO:0043433\|GO:0001649\|GO:0007389\|GO:0090179\|GO:0010950\|GO:0090175\|GO:0010551\|GO:0030278\|GO:0007165\|GO:0035121\|GO:0001944\|GO:0007601\|GO:0005737\|GO:0005576\|GO:0005615   NP_003006      Secreted frizzled-related protein 5                                 2.7   6.7

  mRNA under-expressed in lonely Individuals                                                                                                                                                                                                                                                                                                                                                                         
  -------------------------------------------- -------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------- ---------------------------------------- ------ ------
  TFF1                                         7031     Hs.162807   GO:0008083\|GO:0005975\|GO:0007586\|GO:0030277\|GO:0032355\|GO:0010039\|GO:0043434\|GO:0006950\|GO:0005576\|GO:0005615                                                                                                                                                               NP_003216   Trefoil factor 1                         −2.0   −4.0
  CXCR6                                        10663    Hs.34526    GO:0016494\|GO:0004930\|GO:0015026\|GO:0007186\|GO:0019079\|GO:0005887\|GO:0005886\|GO:0005886                                                                                                                                                                                       NP_006555   Chemokine (C-X-C motif) receptor 6       −2.0   −4.0
  DMP1                                         1758     Hs.652366   GO:0005509\|GO:0050840\|GO:0005178\|GO:0031214\|GO:0030198\|GO:0001503\|GO:0010811\|GO:0005737\|GO:0005576\|GO:0005634\|GO:0005578                                                                                                                                                   NP_004398   Dentin matrix acidic phosphoprotein 1    −2.1   −4.2
  HIST4H4                                      121504   Hs.718935                                                                                                                                                                                                                                                                                        NP_778224   Histone cluster 4, H4                    −2.1   −4.2
  CIAPIN1                                      57019    Hs.4900     GO:0006916\|GO:0006915\|GO:0030097\|GO:0005737\|GO:0005737\|GO:0005730\|GO:0005634                                                                                                                                                                                                   NP_064709   Cytokine induced apoptosis inhibitor 1   −2.1   −4.2
  MPO                                          4353     Hs.458272   GO:0003682\|GO:0020037\|GO:0008201\|GO:0046872\|GO:0016491\|GO:0004601\|GO:0006916\|GO:0006952\|GO:0050832\|GO:0042744\|GO:0002149\|GO:0034374\|GO:0044130\|GO:0055114\|GO:0019430\|GO:0002679\|GO:0006979\|GO:0001878\|GO:0005615\|GO:0005764\|GO:0005739\|GO:0005634\|GO:0030141   NP_000241   Myeloperoxidase                          −2.1   −4.3
  HAMP                                         57817    Hs.8821     GO:0005179\|GO:0006879\|GO:0042742\|GO:0050832\|GO:0006955\|GO:0031640\|GO:0045179\|GO:0005737\|GO:0005576                                                                                                                                                                           NP_066998   Hepcidin antimicrobial peptide           −2.3   −5.0
  DENND2C                                      163259   Hs.654928                                                                                                                                                                                                                                                                                        NP_940861   DENN/MADD domain containing 2C           −2.4   −5.3
  ZDBF2                                        57683    Hs.110489   GO:0046872\|GO:0003676\|GO:0008270                                                                                                                                                                                                                                                   NP_065974   Zinc finger, DBF-type containing 2       −2.5   −5.5
  DEFA3                                        1668     Hs.654448   GO:0042742\|GO:0050832\|GO:0031640\|GO:0009615\|GO:0005576\|GO:0005615                                                                                                                                                                                                               NP_005208   Defensin, alpha 3, neutrophil-specific   −3.1   −8.6
